Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors

被引:29
|
作者
Lv, Xiaoqing [1 ]
Ying, Huazhou [1 ]
Ma, Xiaodong [1 ]
Qiu, Ni [1 ]
Wu, Peng [1 ]
Yang, Bo [1 ]
Hu, Yongzhou [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Zhejiang, Peoples R China
关键词
PI3K; mTOR; Cancer; Inhibitor; 4-Alkynyl-quinoline; PI3K-ALPHA INHIBITORS; CANCER MUTATIONS; MTOR INHIBITORS; IN-VIVO; DISCOVERY; PI3K; POTENT; RAPAMYCIN; TARGET; CHALLENGES;
D O I
10.1016/j.ejmech.2015.05.025
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel series of 4-alkynyl-quinoline derivatives were designed, synthesized and biologically evaluated for their PI3K alpha inhibitory activities and anti-proliferative effects against two cancer cell lines PC-3 and HCT-116. Most of them showed potent PI3K alpha inhibitory activities with IC50 values at low nanomolar level and good to excellent anti-proliferative effects against both cell lines. Among them, compound 15d, the most potent one, was selected for further biological evaluation. As a result, 15d displayed strong inhibitory activity against other class I PI3K isoforms (PI3K beta, PI3K gamma and PI3K delta) and mTOR with an acceptable kinase selectivity profile. Moreover, the western blot assay indicated that the phosphorylation of Akt, another downstream effector of PI3K, can be remarkably suppressed by 15d at cellular level. All these experimental results suggested that 15d is a potent PI3K/mTOR dual inhibitor and could serve as a promising lead compound for the development of anticancer agents. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:36 / 50
页数:15
相关论文
共 50 条
  • [31] Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold
    Ma, Mengyan
    Feng, Yifan
    Zhang, San-Qi
    Duan, Weiming
    Gao, Li
    Yuan, Bo
    Xin, Minhang
    FUTURE MEDICINAL CHEMISTRY, 2023, 15 (16) : 1491 - 1509
  • [32] Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors
    Alvarez, Rosa M.
    Belen Garcia, Ana
    Riesco-Fagundo, Concepcion
    Martin, Jose, I
    Varela, Carmen
    Rodriguez Hergueta, Antonio
    Gonzalez Cantalapiedra, Esther
    Oyarzabal, Julen
    Di Geronimo, Bruno
    Lorenzo, Milagros
    Isabel Albarran, M.
    Cebria, Antonio
    Cebrian, David
    Martinez-Gonzalez, Sonia
    Blanco-Aparicio, Carmen
    Pastor, Joaquin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [33] Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα, inhibitors
    Zhu, Wufu
    Chen, Chen
    Sun, Chengyu
    Xu, Shan
    Wu, Chunjiang
    Lei, Fei
    Xia, Hui
    Tu, Qidong
    Zheng, Pengwu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 93 : 64 - 73
  • [34] PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
    Alzahrani, Ali S.
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 125 - 132
  • [35] Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR
    Yu, Tao
    Li, Ning
    Wu, Chengde
    Guan, Amy
    Li, Yi
    Peng, Zhengang
    He, Miao
    Li, Jie
    Gong, Zhen
    Huang, Lei
    Gao, Bo
    Hao, Dongling
    Sun, Jikui
    Pan, Yan
    Shen, Liang
    Chan, Chichung
    Lu, Xiulian
    Yuan, Hongyu
    Li, Yongguo
    Li, Jian
    Chen, Shuhui
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (03): : 256 - 261
  • [36] Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation
    Ma, Xiao-Dong
    Qiu, Ni
    Yang, Bo
    He, Qiao-Jun
    Hu, Yong-Zhou
    MEDCHEMCOMM, 2016, 7 (02) : 297 - 310
  • [37] Apitolisib. Dual PI3K/mTOR inhibitor, Oncolytic
    de Lartigue, Jane
    DRUGS OF THE FUTURE, 2013, 38 (10) : 671 - 678
  • [38] 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
    Liu, Kevin K-C.
    Bagrodia, Shubha
    Bailey, Simon
    Cheng, Hengmiao
    Chen, Hui
    Gao, Lisa
    Greasley, Samantha
    Hoffman, Jacqui E.
    Hu, Qiyue
    Johnson, Ted O.
    Knighton, Dan
    Liu, Zhengyu
    Marx, Matthew A.
    Nambu, Mitchell D.
    Ninkovic, Sacha
    Pascual, Bernadette
    Rafidi, Kristina
    Rodgers, Caroline M-L.
    Smith, Graham L.
    Sun, Shaoxian
    Wang, Haitao
    Yang, Anle
    Yuan, Jing
    Zou, Aihua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (20) : 6096 - 6099
  • [39] Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors
    Zhang, Binliang
    Zhang, Qian
    Xiao, Zhen
    Sun, Xin
    Yang, Zunhua
    Gu, Qi
    Liu, Ziqin
    Xie, Ting
    Jin, Qingqing
    Zheng, Pengwu
    Xu, Shan
    Zhu, Wufu
    BIOORGANIC CHEMISTRY, 2020, 95
  • [40] Recent Updates on Morpholino Pyrimidine Derivatives as Promising PI3K/Akt/mTOR Inhibitors
    Keertika, Khandelwal
    Behera, Swagatika
    Sharma, Nutan
    CHEMISTRY AFRICA-A JOURNAL OF THE TUNISIAN CHEMICAL SOCIETY, 2025, 8 (02): : 369 - 395